<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01211730</url>
  </required_header>
  <id_info>
    <org_study_id>STU00005806</org_study_id>
    <nct_id>NCT01211730</nct_id>
  </id_info>
  <brief_title>Study of Glycemic Control on Liver Transplantation Outcomes</brief_title>
  <official_title>Prospective, Randomized, Open-Label, Controlled Study to Evaluate the Safety and Efficacy of Intensive Glycemic Control on Outcomes Following Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many but not all studies have shown improvement in morbidity and mortality with intensive
      glycemic management postoperatively. In this study, the investigators propose to determine
      whether improved glycemic control using intensive insulin treatment immediately
      postoperatively will improve outcomes in patients undergoing liver transplant using a
      prospective, controlled, randomized, parallel-group study design targeting two different
      glucose levels, 140 and 180 mg/dL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many studies have shown improvement in morbidity and mortality with intensive glycemic
      management postoperatively. However, some recent studies have not been able to reproduce
      these benefits and have raised the issue of adverse consequences of hypoglycemia associated
      with intensive therapy. Our own data show an association of increased graft rejection
      proportional to postoperative glucose levels in patients who have undergone a liver
      transplant. Preliminary data suggest that this may improved by better glycemic control using
      the Glucose Management Service here at Northwestern.

      In this study, we propose to determine whether improved glycemic control using intensive
      insulin treatment immediately postoperatively will improve outcomes in patients undergoing
      liver transplant using a prospective, controlled, randomized, parallel-group study design
      targeting two different glucose levels, 140 and 180 mg/dL. Postoperative glucose management
      with insulin will be supervised by the Glucose Management Service as is routine, with the
      only research aspect being the two different glucose targets and the outcome analysis with
      liver transplant rejection as the primary outcome and infections and hypoglycemia being the
      principle secondary outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rejection of Liver Transplant</measure>
    <time_frame>within 1 year of transplantation</time_frame>
    <description>Liver transplant rejection determined by either biopsy or clinical criteria (&gt;2x transaminases, clinical decision, treatment with high dose steroids and other anti-rejection medications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia</measure>
    <time_frame>Within first 3 days following transplantation</time_frame>
    <description>Participants experiencing hypoglycemia (glucose &lt; 70 mg/dL) within the first 3- days following transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection Rates</measure>
    <time_frame>Within 1 year following transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehospitalization Rates</measure>
    <time_frame>Within 1 year following transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Graft Survival at 1 Year</measure>
    <time_frame>1 year following transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death Within 1 Year</measure>
    <time_frame>1 year</time_frame>
    <description>Death following liver transplant between 1 day and 1 year</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">164</enrollment>
  <condition>Evidence of Liver Transplantation</condition>
  <condition>Hyperglycemia</condition>
  <condition>Rejection</condition>
  <arm_group>
    <arm_group_label>140 Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin treatment to target blood glucose at 140 mg/dl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>180 Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin treatment to target blood glucose at 180 mg/dl</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.</description>
    <arm_group_label>140 Group</arm_group_label>
    <arm_group_label>180 Group</arm_group_label>
    <other_name>glargine insulin</other_name>
    <other_name>aspart insulin</other_name>
    <other_name>Lantus insulin</other_name>
    <other_name>Novolog insulin</other_name>
    <other_name>Detemir insulin</other_name>
    <other_name>Levemir insulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Require Liver Transplantation

          2. Age 18 - 80

          3. Able to give informed consent personally or via a family member who has appropriate
             authorization to do so if patient unconscious.

          4. Expected survival following transplantation for &gt; 1 year.

          5. Glucose level over 180 mg/dL postoperatively

        Exclusion Criteria:

          1. Inability of patient or family member to give informed consent

          2. Not expected to survive for &gt; 1 year following liver transplantation.

          3. Previous liver transplantation

          4. Acute liver failure

          5. Living related donor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark E Molitch, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University Feinberg School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2010</study_first_submitted>
  <study_first_submitted_qc>September 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2010</study_first_posted>
  <results_first_submitted>September 12, 2016</results_first_submitted>
  <results_first_submitted_qc>October 31, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 23, 2016</results_first_posted>
  <last_update_submitted>October 31, 2016</last_update_submitted>
  <last_update_submitted_qc>October 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Mark Molitch</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Liver</keyword>
  <keyword>transplantation</keyword>
  <keyword>Glucose</keyword>
  <keyword>Hyperglycemia</keyword>
  <keyword>Insulin</keyword>
  <keyword>Rejection</keyword>
  <keyword>Hypoglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were primarily recruited from Liver Transplant Clinic and the inpatient Liver Transplant service</recruitment_details>
      <pre_assignment_details>Of 278 patients Consented, 46 died before transplant, 38 did not undergo transplant, 14 were delisted for transplant, and 16 did not enter the study for miscellaneous reasons.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>140 Group</title>
          <description>Insulin treatment to target blood glucose at 140 mg/dl
Insulin: Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.</description>
        </group>
        <group group_id="P2">
          <title>180 Group</title>
          <description>Insulin treatment to target blood glucose at 180 mg/dl
Insulin: Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients undergoing liver transplantation</population>
      <group_list>
        <group group_id="B1">
          <title>140 Group</title>
          <description>Insulin treatment to target blood glucose at 140 mg/dl
Insulin: Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.</description>
        </group>
        <group group_id="B2">
          <title>180 Group</title>
          <description>Insulin treatment to target blood glucose at 180 mg/dl
Insulin: Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
            <count group_id="B2" value="82"/>
            <count group_id="B3" value="164"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.1" spread="8.0"/>
                    <measurement group_id="B2" value="56.9" spread="7.6"/>
                    <measurement group_id="B3" value="57.5" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>body mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.3" spread="6.0"/>
                    <measurement group_id="B2" value="30.0" spread="6.6"/>
                    <measurement group_id="B3" value="30.1" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Model for End-stage Liver DIsease (MELD) Score</title>
          <description>The MELD Score uses the patient's values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival. It is calculated according to the following formula: MELD = 3.78×ln[serum bilirubin (mg/dL)] + 11.2×ln[INR] + 9.57×ln[serum creatinine (mg/dL)] + 6.43.
In interpreting the MELD Score in hospitalized patients, the 3 month mortality is:
40 or more — 71.3% mortality 30–39 — 52.6% mortality 20–29 — 19.6% mortality 10–19 — 6.0% mortality &lt;9 — 1.9% mortality</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.3" spread="9.4"/>
                    <measurement group_id="B2" value="28.2" spread="7.6"/>
                    <measurement group_id="B3" value="27.8" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Liver only Transplant</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Liver Only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver Plus Kidney</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hepatitis C positive</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hepatitis C Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis C Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rejection of Liver Transplant</title>
        <description>Liver transplant rejection determined by either biopsy or clinical criteria (&gt;2x transaminases, clinical decision, treatment with high dose steroids and other anti-rejection medications</description>
        <time_frame>within 1 year of transplantation</time_frame>
        <population>Patients undergoing liver transplant</population>
        <group_list>
          <group group_id="O1">
            <title>140 Group</title>
            <description>Insulin treatment to target blood glucose at 140 mg/dl
Insulin: Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.</description>
          </group>
          <group group_id="O2">
            <title>180 Group</title>
            <description>Insulin treatment to target blood glucose at 180 mg/dl
Insulin: Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.</description>
          </group>
        </group_list>
        <measure>
          <title>Rejection of Liver Transplant</title>
          <description>Liver transplant rejection determined by either biopsy or clinical criteria (&gt;2x transaminases, clinical decision, treatment with high dose steroids and other anti-rejection medications</description>
          <population>Patients undergoing liver transplant</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.709</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycemia</title>
        <description>Participants experiencing hypoglycemia (glucose &lt; 70 mg/dL) within the first 3- days following transplantation</description>
        <time_frame>Within first 3 days following transplantation</time_frame>
        <population>Patients having liver transplant</population>
        <group_list>
          <group group_id="O1">
            <title>140 Group</title>
            <description>Insulin treatment to target blood glucose at 140 mg/dl
Insulin: Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.</description>
          </group>
          <group group_id="O2">
            <title>180 Group</title>
            <description>Insulin treatment to target blood glucose at 180 mg/dl
Insulin: Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemia</title>
          <description>Participants experiencing hypoglycemia (glucose &lt; 70 mg/dL) within the first 3- days following transplantation</description>
          <population>Patients having liver transplant</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infection Rates</title>
        <time_frame>Within 1 year following transplantation</time_frame>
        <population>patients having had liver transplants</population>
        <group_list>
          <group group_id="O1">
            <title>140 Group</title>
            <description>Insulin treatment to target blood glucose at 140 mg/dl
Insulin: Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.</description>
          </group>
          <group group_id="O2">
            <title>180 Group</title>
            <description>Insulin treatment to target blood glucose at 180 mg/dl
Insulin: Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.</description>
          </group>
        </group_list>
        <measure>
          <title>Infection Rates</title>
          <population>patients having had liver transplants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0046</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rehospitalization Rates</title>
        <time_frame>Within 1 year following transplantation</time_frame>
        <population>patients undergoing liver transplant</population>
        <group_list>
          <group group_id="O1">
            <title>140 Group</title>
            <description>Insulin treatment to target blood glucose at 140 mg/dl
Insulin: Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.</description>
          </group>
          <group group_id="O2">
            <title>180 Group</title>
            <description>Insulin treatment to target blood glucose at 180 mg/dl
Insulin: Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.</description>
          </group>
        </group_list>
        <measure>
          <title>Rehospitalization Rates</title>
          <population>patients undergoing liver transplant</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.75</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Graft Survival at 1 Year</title>
        <time_frame>1 year following transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>140 Group</title>
            <description>Insulin treatment to target blood glucose at 140 mg/dl
Insulin: Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.</description>
          </group>
          <group group_id="O2">
            <title>180 Group</title>
            <description>Insulin treatment to target blood glucose at 180 mg/dl
Insulin: Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Graft Survival at 1 Year</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death Within 1 Year</title>
        <description>Death following liver transplant between 1 day and 1 year</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>140 Group</title>
            <description>Insulin treatment to target blood glucose at 140 mg/dl
Insulin: Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.</description>
          </group>
          <group group_id="O2">
            <title>180 Group</title>
            <description>Insulin treatment to target blood glucose at 180 mg/dl
Insulin: Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.</description>
          </group>
        </group_list>
        <measure>
          <title>Death Within 1 Year</title>
          <description>Death following liver transplant between 1 day and 1 year</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.77</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1st 30 days following transplant. This is the time of the insulin/glucose intervention</time_frame>
      <desc>the major adverse event of the intervention was hypoglycemia, which is described in outcomes. There were no adverse sequelae of any of the hypoglycemic events</desc>
      <group_list>
        <group group_id="E1">
          <title>140 Group</title>
          <description>Insulin treatment to target blood glucose at 140 mg/dl
Insulin: Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.</description>
        </group>
        <group group_id="E2">
          <title>180 Group</title>
          <description>Insulin treatment to target blood glucose at 180 mg/dl
Insulin: Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>death within 1 year of transplant</sub_title>
                <description>Deaths occurring within one year of transplant</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Readmission within one year</sub_title>
                <description>Hospital readmission within one year</description>
                <counts group_id="E1" events="48" subjects_affected="48" subjects_at_risk="82"/>
                <counts group_id="E2" events="51" subjects_affected="51" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver Graft Failure within 1 year of transplant</sub_title>
                <description>Failure of the Liver graft within 1 year of transplant</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections within one year of transplant</sub_title>
                <description>Infection in any organ within one year of transplant</description>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="82"/>
                <counts group_id="E2" events="54" subjects_affected="54" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Single-center study with experienced nurses, glucose management service and endocrinologists. May not be applicable to other care settings</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mark E. Molitch, M.D.</name_or_title>
      <organization>Northwestern University Feinberg School of Medicine</organization>
      <phone>312 503-4130</phone>
      <email>molitch@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

